Overview

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Everolimus
Sirolimus